American Heart Journal
Volume 156, Issue 6 , Pages 1184-1190 , December 2008

Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study

Received 21 March 2008 ,Accepted 10 July 2008.

References 

  1. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic HF and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–771
  2. The Cardiac Insufficiency Bisoprolol Study II Investigators . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
  3. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive HF in the community. A study of all incident cases in Olmsted Country, Minnesota in 1991. Circulation. 1998;98:2282–2289
  4. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with HF. N Engl J Med. 2002;347:1397–1402
  5. Permanyer Miralda G, Soriano N, Brotons C, et al. Baseline characteristics and determinants of outcomes in a patient population admitted for HF to a general hospital. Rev Esp Cardiol. 2002;55:571–578
  6. Grigorian Shamagian L, Gonzalez-Juanatey JR, Varela Roman A, et al. The death rate among hospitalized HF patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. Eur Heart J. 2005;26:2251–2258
  7. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with HF: survival trends in 12,220 index admissions in Leicestershire 1993-2001. Heart. 2003;89:615–620
  8. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in HF: trends in case fatality in 66,547 patients hospitalized between 1986-1995. Circulation. 2000;102:1126–1131
  9. Schaufelberger M, Swedberg K, Koster M, et al. Decreasing one-year mortality and hospitalization rates for HF in Sweden; data from the Swedish Hospital discharge registry 1988 to 2000. Eur Heart J. 2004;25:300–307
  10. Lee DS, Mamdani MM, Austin PC Gong Y, et al. Trends in HF outcomes and pharmacotherapy: 1992 to 2000. Am J Med. 2004;116:581–589
  11. Baker DW, Einstadter D, Thomas C, et al. Mortality trends for 23,505 Medicare patients hospitalized with HF in Northeast Ohio, 1991 to 1997. Am Heart J. 2003;146:258–264
  12. Lenzen MJ, Scholte op Reimer WJM, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHF Survey. Eur Heart J. 2004;25:1214–1220
  13. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive HF in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948–1955
  14. Ahmed A, Roseman JM, Duxbury AS, et al. Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with HF. Am Heart J. 2002;144:365–372
  15. Martinez-Selles M, Garcia Robles J, Prieto L, et al. Hospitalized congestive HF patients with preserved versus abnormal left ventricular systolic function. Rev Esp Cardiol. 2002;55:579–586
  16. Bhatia RS, Tu JV, Lee DS, et al. Outcome of HF with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–269
  17. Varela-Roman A, Grigorian Shamagian L, Barge E, et al. HF in patients with preserved and deteriorated left ventricular ejection fraction: long term prognosis. Heart. 2005;91:489–494
  18. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of HF with preserved ejection fraction. N Engl J Med. 2006;355:251–259
  19. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left-ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  20. Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in HF patients: the Candesartan in HF patients: the Candesartan in HF Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004;110:2180–2183
  21. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic HF: executive summary (update 2005). Eur Heart J. 2005;26:1115–1140
  22. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the diagnosis and management of chronic HF in the adult. Circulation. 2005;112:e154–e235
  23. Banerjee P, Banerjee T, Khand A, et al. Diastolic HF: neglected or misdiagnosed. J Am Coll Cardiol. 2002;39:138–141
  24. Hogg K, Swedberg K, McMurray JJ. HF with preserved left ventricular systolic function. J Am Coll Cardiol. 2004;43:317–327
  25. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic HF and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777–781
  26. Grigorian Shamagian L, Varela Roman A, Mazon Ramos P, et al. Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive HF who have preserved systolic function: a long-term follow-up study. J Card Fail. 2006;12:128–133
  27. Klapholz M, Maurer M, Lowe AM, et al. Hospitalization for HF in the presence of a normal left ventricular ejection fraction. J Am Coll Cardiol. 2004;43:1432–1438

PII: S0002-8703(08)00627-3

doi: 10.1016/j.ahj.2008.07.011

American Heart Journal
Volume 156, Issue 6 , Pages 1184-1190 , December 2008

Article Tools

* Image Usage & Resolution